AZNAstraZenecaSigning up patients
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
ER-Positive HER2-Negative Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 150 (planned)
- Started
- Jun 15, 2026
- Main results expected
- Feb 28, 2029
- Fully finished
- Feb 28, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Efficacy of camizestrant and ribociclib by time to next treatment (TTNT)
Measured over: Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07647328 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC